The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review
Authors:
- Ioana Maria AndrioaieIAIoana Maria Andrioaie
- Ionut LuchianIonut Luchian
- Costin DămianCDCostin Dămian
- Giorgio NichiteanGNGiorgio Nichitean
- Elena Porumb AndreseEAElena Porumb Andrese
- Theodor Florin PantilimonescuTheodor Florin Pantilimonescu
- Bogdan TrandabățBTBogdan Trandabăț
- Liviu Jany PrisacariuLPLiviu Jany Prisacariu
- Dana Gabriela BudalăDana Gabriela Budală
- Daniela Cristina DimitriuDDDaniela Cristina Dimitriu
- Luminita Smaranda IancuLILuminita Smaranda Iancu
- Ramona Gabriela UrsuRamona Gabriela Ursu
Open Access
Abstract
Human papillomavirus (HPV) is recognized as being related to a wide variety of known cancers: cervical, oropharyngeal, anal, vaginal, penile, and skin. For some of these cancers, rigorous algorithms for screening, therapeutical interventions, and follow-up procedures have been established. Vaccination using the nonvalent anti-HPV vaccine, which prevents infection regarding the most frequently involved high-risk HPV types (16, 18, 31, 33, 45, 52, and 58) and low-risk HPV types (6 and 11), has also extensively prevented, controlled, and even eradicated HPV infections. Still, even with all of these multidisciplinary interventions, the burden of HPV cancers is still high worldwide. The circulating DNA of HPV-induced cancers is thought to be an adequate biomarker for optimizing the control of these virus-related cancers. We analyzed the literature published in the last 5 years regarding ctDNA and four of the above-mentioned cancers. The most frequently used assay for ctDNA detection was the droplet digital PCR assay, used for the management of therapy in the late stages of cancer. ctDNA could not be used for early detection in any of the studied cancers. The OPSCCs were the most frequent cancers analyzed via ctDNA assays. Larger, properly designed cohort studies might establish the clinical utility of this biomarker.Keywords
This publication has 83 references indexed in Scilit:
- HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 PatientsJNCI: Journal of the National Cancer Institute, 2016
- Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM StudyEuropean Urology, 2016
- Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?Clinical Microbiology and Infection, 2015
- The Need for Cervical Cancer Control in HIV-Positive and HIV-Negative Women from Romania by Primary Prevention and by Early Detection Using Clinically Validated HPV/DNA TestsPLOS ONE, 2015
- Long-term Persistence of Oral Human Papillomavirus Type 16: The HPV Infection in Men (HIM) StudyCancer Prevention Research, 2015
- Human papillomavirus type 38 E6 and E7 act as tumour promoters during chemically induced skin carcinogenesisJournal of General Virology, 2013
- Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort studyThe Lancet, 2011
- Circulating tumour cells in cancer patients: challenges and perspectivesTrends in Molecular Medicine, 2010
- Validation of high-risk HPV tests for primary cervical screeningJournal of Clinical Virology, 2009
- Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and olderInternational Journal of Cancer, 2008